Identification

Name
Aldosterone
Accession Number
DB04630
Type
Small Molecule
Groups
Experimental, Investigational
Description

A hormone secreted by the adrenal cortex that regulates electrolyte and water balance by increasing the renal retention of sodium and the excretion of potassium. [PubChem]

Structure
Thumb
Synonyms
  • (+)-aldosterone
  • 11beta,21-Dihydroxy-3,20-diketo-4-pregnen-18-al
  • 11beta,21-Dihydroxy-3,20-diketopregn-4-ene-18-al
  • 11beta,21-dihydroxy-3,20-dioxo-4-pregnen-18-al
  • 11beta,21-dihydroxy-3,20-dioxo-pregn-4-ene-18-al
  • 11beta,21-dihydroxy-3,20-dioxopregn-4-en-18-al
  • 11beta,21-Dihydroxypregn-4-ene-3,18,20-trione
  • 18-Aldocorticosterone
  • 18-Formyl-11beta,21-dihydroxy-4-pregnene-3,20-dione
  • 18-Oxocorticosterone
  • Aldocorten
  • Aldocortene
  • Aldocortin
  • Aldosterona
  • Aldosteronum
  • D-aldosterone
  • Electrocortin
  • Elektrocortin
Categories
UNII
4964P6T9RB
CAS number
52-39-1
Weight
Average: 360.444
Monoisotopic: 360.193674006
Chemical Formula
C21H28O5
InChI Key
PQSUYGKTWSAVDQ-ZVIOFETBSA-N
InChI
InChI=1S/C21H28O5/c1-20-7-6-13(24)8-12(20)2-3-14-15-4-5-16(18(26)10-22)21(15,11-23)9-17(25)19(14)20/h8,11,14-17,19,22,25H,2-7,9-10H2,1H3/t14-,15-,16+,17-,19+,20-,21+/m0/s1
IUPAC Name
(1S,2R,10S,11S,14S,15R,17S)-17-hydroxy-14-(2-hydroxyacetyl)-2-methyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-ene-15-carbaldehyde
SMILES

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics

At the late distal tubule and collecting duct, aldosterone has two main actions: 1) aldosterone acts on mineralocorticoid receptors (MR) on principal cells in the distal tubule of the kidney nephron, increasing the permeability of their apical (luminal) membrane to potassium and sodium and activates their basolateral Na+/K+ pumps, stimulating ATP hydrolysis leading to phosphorylation of the pump and a conformational change in the pump exposes the Na+ ions to the outside. The phosphorylated form of the pump has a low affinity for Na+ ions, hence reabsorbing sodium (Na+) ions and water into the blood, and secreting potassium (K+) ions into the urine; 2) aldosterone stimulates H+ secretion by intercalated cells in the collecting duct, regulating plasma bicarbonate (HCO3−) levels and its acid/base balance; and 3) aldosterone may act on the central nervous system via the posterior pituitary gland to release vasopressin (ADH) which serves to conserve water by direct actions on renal tubular resorption.

Mechanism of action
TargetActionsOrganism
UMineralocorticoid receptorNot AvailableHuman
UGlucocorticoid receptorNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Aldosterone is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Aldosterone.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Aldosterone.Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Aldosterone.Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Aldosterone.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Aldosterone.Approved, Withdrawn
AldesleukinAldosterone may decrease the antineoplastic activities of Aldesleukin.Approved
AlgeldrateThe bioavailability of Aldosterone can be decreased when combined with Algeldrate.Approved, Experimental
AlmagateThe bioavailability of Aldosterone can be decreased when combined with Almagate.Experimental
AlmasilateThe bioavailability of Aldosterone can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Aldosterone.Experimental
AloglutamolThe bioavailability of Aldosterone can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Aldosterone.Experimental
AluminiumThe bioavailability of Aldosterone can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Aldosterone can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Aldosterone can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Aldosterone can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Aldosterone is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Aldosterone.Approved
Amphotericin BAldosterone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Aldosterone.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Aldosterone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Aldosterone.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Aldosterone.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Aldosterone.Approved, Investigational
AprepitantThe serum concentration of Aldosterone can be increased when it is combined with Aprepitant.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Aldosterone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Aldosterone.Withdrawn
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Aldosterone.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when Aldosterone is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Aldosterone.Experimental
BendroflumethiazideAldosterone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Aldosterone.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Aldosterone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Aldosterone.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Aldosterone.Experimental
Bismuth SubcitrateThe bioavailability of Aldosterone can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Aldosterone can be decreased when combined with Bismuth subnitrate.Experimental
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Aldosterone.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Aldosterone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Aldosterone.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Aldosterone.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Aldosterone.Experimental
BumetanideAldosterone may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Aldosterone.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Aldosterone can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Aldosterone can be decreased when combined with Calcium silicate.Experimental
Capromab pendetideAldosterone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Aldosterone.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Aldosterone.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Aldosterone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Aldosterone.Approved, Investigational
CeritinibAldosterone may increase the hyperglycemic activities of Ceritinib.Approved
ChlorothiazideAldosterone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Aldosterone can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorthalidoneAldosterone may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Aldosterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Aldosterone.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Cinoxacin.Approved, Investigational, Withdrawn
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Aldosterone.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Aldosterone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ColesevelamColesevelam can cause a decrease in the absorption of Aldosterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Aldosterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of Aldosterone can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Aldosterone.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Aldosterone is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Aldosterone is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Aldosterone.Investigational
CyclopenthiazideAldosterone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Aldosterone.Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Aldosterone.Approved
DaidzeinThe serum concentration of Aldosterone can be increased when it is combined with Daidzein.Experimental
DarunavirThe serum concentration of Aldosterone can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Aldosterone is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Aldosterone is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Aldosterone is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Aldosterone.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Aldosterone is combined with Dichlorvos.Vet Approved
DienestrolThe serum concentration of Aldosterone can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of Aldosterone can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Aldosterone.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Aldosterone.Approved
DistigmineThe risk or severity of adverse effects can be increased when Aldosterone is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Aldosterone is combined with Donepezil.Approved
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Aldosterone.Approved, Investigational
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Aldosterone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Aldosterone.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Aldosterone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Aldosterone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Aldosterone is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Enoxacin.Approved, Investigational
EpimestrolThe serum concentration of Aldosterone can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Aldosterone.Approved
EquolThe serum concentration of Aldosterone can be increased when it is combined with Equol.Investigational
EstradiolThe serum concentration of Aldosterone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Aldosterone can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
EstroneThe serum concentration of Aldosterone can be increased when it is combined with Estrone.Approved
Etacrynic acidAldosterone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Aldosterone.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Aldosterone.Experimental
Ethinyl EstradiolThe serum concentration of Aldosterone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Aldosterone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Aldosterone.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Aldosterone.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Aldosterone.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Aldosterone.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Aldosterone.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Aldosterone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Aldosterone.Approved
FenthionThe risk or severity of adverse effects can be increased when Aldosterone is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Aldosterone.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Aldosterone.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Aldosterone.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Aldosterone.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Aldosterone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Aldosterone.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Aldosterone.Experimental
FluoxymesteroneAldosterone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Aldosterone.Approved, Investigational
FosaprepitantThe serum concentration of Aldosterone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Aldosterone can be decreased when it is combined with Fosphenytoin.Approved
FurosemideAldosterone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Aldosterone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Aldosterone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Aldosterone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Aldosterone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Aldosterone is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Aldosterone is combined with Ginkgo biloba.Approved, Investigational, Nutraceutical
GLPG-0492Aldosterone may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Aldosterone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Aldosterone.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Aldosterone.Experimental
HexestrolThe serum concentration of Aldosterone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Aldosterone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Aldosterone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Aldosterone.Approved, Investigational
HydrochlorothiazideAldosterone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideAldosterone may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Aldosterone can be decreased when combined with Hydrotalcite.Experimental, Investigational
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Aldosterone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Aldosterone.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Aldosterone.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Aldosterone.Approved
IndapamideAldosterone may increase the hypokalemic activities of Indapamide.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Aldosterone.Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Aldosterone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Aldosterone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Aldosterone is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Aldosterone is combined with Ipidacrine.Experimental
IsoflurophateThe risk or severity of adverse effects can be increased when Aldosterone is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Aldosterone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Aldosterone.Withdrawn
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Aldosterone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Aldosterone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Aldosterone.Approved
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Aldosterone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Aldosterone.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Levofloxacin.Approved, Investigational
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Aldosterone.Approved
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Aldosterone.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Aldosterone.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Aldosterone.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Aldosterone.Approved, Investigational
LumacaftorThe serum concentration of Aldosterone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Aldosterone.Approved, Investigational
MagaldrateThe bioavailability of Aldosterone can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe bioavailability of Aldosterone can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Aldosterone can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Aldosterone can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Aldosterone.Approved
Magnesium silicateThe bioavailability of Aldosterone can be decreased when combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe bioavailability of Aldosterone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Aldosterone is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Aldosterone.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Aldosterone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Aldosterone.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Aldosterone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Aldosterone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Aldosterone.Approved
MesteroloneAldosterone may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Aldosterone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Aldosterone.Investigational, Withdrawn
MethallenestrilThe serum concentration of Aldosterone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Aldosterone is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideAldosterone may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Aldosterone is combined with Methyl salicylate.Approved, Vet Approved
MethyltestosteroneAldosterone may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Aldosterone is combined with Metoclopramide.Approved, Investigational
MetolazoneAldosterone may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Aldosterone can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Aldosterone is combined with Minaprine.Approved
MitotaneThe serum concentration of Aldosterone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Aldosterone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Aldosterone.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Aldosterone.Experimental
MoxestrolThe serum concentration of Aldosterone can be increased when it is combined with Moxestrol.Experimental
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Aldosterone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Aldosterone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Aldosterone.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Aldosterone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Aldosterone is combined with Nalidixic Acid.Approved, Investigational
NandroloneAldosterone may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Aldosterone.Approved, Vet Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Nemonoxacin.Investigational
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Aldosterone.Approved
NevirapineThe serum concentration of Aldosterone can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Aldosterone is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Aldosterone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Aldosterone.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Aldosterone.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Aldosterone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Norfloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Aldosterone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Aldosterone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Aldosterone.Vet Approved
OxandroloneAldosterone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Aldosterone.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Aldosterone is combined with Oxolinic acid.Experimental
OxymetholoneAldosterone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Aldosterone.Approved, Withdrawn
ParaoxonThe risk or severity of adverse effects can be increased when Aldosterone is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Aldosterone.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Aldosterone.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Aldosterone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Aldosterone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Aldosterone.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Aldosterone.Approved, Investigational
PhysostigmineThe risk or severity of adverse effects can be increased when Aldosterone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Aldosterone.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Aldosterone is combined with Pipemidic acid.Experimental
PiretanideAldosterone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Aldosterone.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Aldosterone is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Aldosterone.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Aldosterone.Experimental
Polyestradiol phosphateThe serum concentration of Aldosterone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideAldosterone may increase the hypokalemic activities of Polythiazide.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Aldosterone.Experimental, Investigational
PrimidoneThe serum concentration of Aldosterone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Aldosterone.Experimental
PromestrieneThe serum concentration of Aldosterone can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Aldosterone.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Aldosterone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Aldosterone.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Aldosterone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Aldosterone is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Aldosterone can be increased when it is combined with Quinestrol.Approved
QuinethazoneAldosterone may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Aldosterone is combined with Rabies virus inactivated antigen, A.Approved
RanolazineThe serum concentration of Aldosterone can be increased when it is combined with Ranolazine.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Aldosterone.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Aldosterone.Approved, Experimental, Investigational
RifabutinThe serum concentration of Aldosterone can be decreased when it is combined with Rifabutin.Approved
RifapentineThe serum concentration of Aldosterone can be decreased when it is combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Aldosterone is combined with Rindopepimut.Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Aldosterone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Aldosterone.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Aldosterone is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Aldosterone is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Aldosterone.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Aldosterone.Approved
SecoisolariciresinolThe serum concentration of Aldosterone can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Aldosterone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Aldosterone.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Aldosterone.Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Sitafloxacin.Experimental, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Aldosterone.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Aldosterone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Aldosterone.Investigational
StanozololAldosterone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Aldosterone can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Aldosterone.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Aldosterone.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Aldosterone.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Aldosterone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Aldosterone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Aldosterone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Aldosterone.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Aldosterone is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Aldosterone.Approved, Withdrawn
TelithromycinThe serum concentration of Aldosterone can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Aldosterone.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Aldosterone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Aldosterone.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Aldosterone.Approved
TG4010The risk or severity of adverse effects can be increased when Aldosterone is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Aldosterone.Approved
TiboloneThe serum concentration of Aldosterone can be increased when it is combined with Tibolone.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Aldosterone.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Aldosterone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Aldosterone.Approved
TorasemideAldosterone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Aldosterone.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Aldosterone.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Aldosterone is combined with Trichlorfon.Vet Approved
TrichlormethiazideAldosterone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Aldosterone.Investigational
TrovafloxacinThe risk or severity of adverse effects can be increased when Aldosterone is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Aldosterone is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Aldosterone.Investigational, Withdrawn
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Aldosterone.Approved, Investigational
VoriconazoleThe serum concentration of Aldosterone can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinAldosterone may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when Aldosterone is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Aldosterone.Approved, Investigational
ZeranolThe serum concentration of Aldosterone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Aldosterone.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Aldosterone.Withdrawn
Zoster vaccineThe risk or severity of adverse effects can be increased when Aldosterone is combined with Zoster vaccine.Approved
Food Interactions
Not Available

References

Synthesis Reference

Jack Fishman, Elliot Hahn, Gregory A. Smith, "Aldosterone biosynthesis inhibitor." U.S. Patent US5120724, issued December, 1969.

US5120724
General References
  1. Williams JS, Williams GH: 50th anniversary of aldosterone. J Clin Endocrinol Metab. 2003 Jun;88(6):2364-72. [PubMed:12788829]
External Links
KEGG Compound
C01780
PubChem Compound
5839
PubChem Substance
46505770
ChemSpider
5633
BindingDB
19214
ChEBI
27584
ChEMBL
CHEMBL273453
Therapeutic Targets Database
DAP001344
PharmGKB
PA164924487
HET
AS4
Wikipedia
Aldosterone
ATC Codes
H02AA01 — Aldosterone
PDB Entries
2aa2 / 2q1h
MSDS
Download (68.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedDiagnosticInflammatory Reaction1
Not AvailableCompletedBasic ScienceDiabetes Mellitus (DM)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)166.5 °CPhysProp
water solubility51.2 mg/L (at 37 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.08HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.148 mg/mLALOGPS
logP1.54ALOGPS
logP1.06ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)13.82ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area91.67 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity96.79 m3·mol-1ChemAxon
Polarizability38.87 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9943
Blood Brain Barrier+0.921
Caco-2 permeable+0.8527
P-glycoprotein substrateSubstrate0.7719
P-glycoprotein inhibitor INon-inhibitor0.738
P-glycoprotein inhibitor IINon-inhibitor0.7441
Renal organic cation transporterNon-inhibitor0.6832
CYP450 2C9 substrateNon-substrate0.8059
CYP450 2D6 substrateNon-substrate0.904
CYP450 3A4 substrateSubstrate0.7278
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9189
CYP450 2D6 inhibitorNon-inhibitor0.9251
CYP450 2C19 inhibitorNon-inhibitor0.9434
CYP450 3A4 inhibitorNon-inhibitor0.8795
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8737
Ames testNon AMES toxic0.9073
CarcinogenicityNon-carcinogens0.9543
BiodegradationNot ready biodegradable0.9279
Rat acute toxicity1.5456 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9242
hERG inhibition (predictor II)Non-inhibitor0.5136
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (12.2 KB)
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - EI-BGC-MSsplash10-06si-0694000000-60e1d35ad11d153b5152
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0596-2961000000-38453356e63a34116d1e

Taxonomy

Description
This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Hydroxysteroids
Direct Parent
21-hydroxysteroids
Alternative Parents
Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 3-oxo delta-4-steroids / 11-beta-hydroxysteroids / Delta-4-steroids / Cyclohexenones / Alpha-hydroxy ketones / Secondary alcohols / Cyclic alcohols and derivatives / Primary alcohols
show 3 more
Substituents
Progestogin-skeleton / 21-hydroxysteroid / 20-oxosteroid / Pregnane-skeleton / 18-oxosteroid / 3-oxo-delta-4-steroid / 3-oxosteroid / Oxosteroid / 11-beta-hydroxysteroid / 11-hydroxysteroid
show 16 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
3-oxo steroid, 11beta-hydroxy steroid, 20-oxo steroid, mineralocorticoid, 21-hydroxy steroid, C21-steroid hormone, 18-oxo steroid (CHEBI:27584) / Pregnane and derivatives [Fig], Mineralocorticoids (C01780) / C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives (LMST02030026)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates targ...
Gene Name
NR3C2
Uniprot ID
P08235
Uniprot Name
Mineralocorticoid receptor
Molecular Weight
107066.575 Da
References
  1. Bruner KL, Derfoul A, Robertson NM, Guerriero G, Fernandes-Alnemri T, Alnemri ES, Litwack G: The unliganded mineralocorticoid receptor is associated with heat shock proteins 70 and 90 and the immunophilin FKBP-52. Recept Signal Transduct. 1997;7(2):85-98. [PubMed:9392437]
  2. Bunda S, Liu P, Wang Y, Liu K, Hinek A: Aldosterone induces elastin production in cardiac fibroblasts through activation of insulin-like growth factor-I receptors in a mineralocorticoid receptor-independent manner. Am J Pathol. 2007 Sep;171(3):809-19. [PubMed:17724138]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Wilson VS, Bobseine K, Lambright CR, Gray LE Jr: A novel cell line, MDA-kb2, that stably expresses an androgen- and glucocorticoid-responsive reporter for the detection of hormone receptor agonists and antagonists. Toxicol Sci. 2002 Mar;66(1):69-81. [PubMed:11861974]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid 11-beta-monooxygenase activity
Specific Function
Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochro...
Gene Name
CYP11B1
Uniprot ID
P15538
Uniprot Name
Cytochrome P450 11B1, mitochondrial
Molecular Weight
57572.44 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid 11-beta-monooxygenase activity
Specific Function
Preferentially catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone.
Gene Name
CYP11B2
Uniprot ID
P19099
Uniprot Name
Cytochrome P450 11B2, mitochondrial
Molecular Weight
57559.62 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid 17-alpha-monooxygenase activity
Specific Function
Conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation ...
Gene Name
CYP17A1
Uniprot ID
P05093
Uniprot Name
Steroid 17-alpha-hydroxylase/17,20 lyase
Molecular Weight
57369.995 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. [PubMed:12387747]
  2. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R: Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem. 1992 Dec 5;267(34):24248-52. [PubMed:1360010]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
Gene Name
SLC22A5
Uniprot ID
O76082
Uniprot Name
Solute carrier family 22 member 5
Molecular Weight
62751.08 Da
References
  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Kanai N, Lu R, Bao Y, Wolkoff AW, Schuster VL: Transient expression of oatp organic anion transporter in mammalian cells: identification of candidate substrates. Am J Physiol. 1996 Feb;270(2 Pt 2):F319-25. [PubMed:8779893]
  2. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [PubMed:8786566]

Drug created on September 11, 2007 11:49 / Updated on November 09, 2017 03:44